iosBio
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
iosBio is pioneering the development of a first-in-class oral Epstein-Barr virus (EBV) vaccine designed to prevent infection, a significant advancement over existing approaches. Leveraging our patented OraPro™ platform for oral delivery and Enhance Surface Display™ technology for rapid immunity, our preclinical data demonstrate class-leading antibody responses against key EBV proteins (gB, gHgL, gHgL-gp42 complex and gp350/220). These antigens were identified and optimized using AI-driven design. Unlike intramuscular vaccines that only mitigate disease, iosBio's oral vaccine elicits a potent mucosal immune response, aiming to block EBV transmission and establish a new standard in preventative care.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}